Genedrive PLC

Epistem signs drug discovery collaboration with Novartis

Shares in biotechnology and research services company, Epistem (AIM: EHP) jumped 16% after the company announced that it had entered into a research and development collaboration with Novartis (VTX:NOVN).

The deal will see Novartis pay Epistem US$4 million in an upfront payment and provide research funding for 2 years to identify new drug targets and therapeutics across a wide range of disease areas.  Epistem will provide its stem cell expertise and drug discovery experience with Novartis’s knowledge of disease pathways and bioinformatics. Novartis will have an option to licence any drug targets in exchange for license fees, milestone payments and royalties.

Matthew Walls, Epistem CEO, commented:

"The collaboration will enable us to accelerate the development of our existing targets with a world class pharmaceutical collaborator and to jointly explore disease opportunities in regenerative medicine".

Quick facts: Genedrive PLC

Price: £0.17

Market: AIM
Market Cap: £5.78 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genedrive PLC named herein, including the promotion by the Company of Genedrive PLC in any Content on the Site, the Company receives from said...



Genedrive receives NHS grant to develop and implement point-of-care test

David Budd, chief executive of Genedrive PLC (LON:GDR) and Bill Newman, Professor of Translational Genomic Medicine at the University of Manchester discuss with Proactive Investors the grant awarded to Genedrive for a point-of-care pharmacogenetic test to avoid antibiotic-related hearing loss...

on 26/6/18

2 min read